RICHMOND, Va., Mar 09, 2007 (BUSINESS WIRE) -- Insmed (NASDAQ:INSM) today announced that it will release its 2006 fourth quarter and year end financial results after market close on Wednesday, March 14, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern Time, on Thursday March 15, at 4:30 p.m. (ET) to discuss the financial results, provide a business update and answer questions.
Individuals interested in listening to the live conference call may do so by dialing (877)407-0782 toll free within the U.S. and Canada, or (201) 689-8567 for international callers.
A telephone replay will be available approximately two hours after the call for two weeks by dialing (877) 660-6853 from the U.S., or (201) 612-7415 for international callers. The account code is 286; the conference number is 234775.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.insmed.com. A replay will be available on the Company's Web site for 90 days.
About Insmed
Insmed Inc. is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com
Insmed Safe Harbor Statement
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding business strategies, growth opportunities for approved or proposed products, plans and objectives of management. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that our product candidates may fail in clinical trials or may not be successfully marketed, we may lack financial resources to complete development of product candidates, we may be unable to raise additional financing necessary to continue current operations competing products may be more successful, demand for new pharmaceutical products may decrease and the biopharmaceutical industry may experience negative market trends. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.
